Intracellular and extracellular TGF-β signaling in cancer: some recent topics

[1]  D. Sheppard,et al.  TGF-β1 Signaling and Tissue Fibrosis. , 2018, Cold Spring Harbor perspectives in biology.

[2]  K. Miyazono,et al.  Pancreatic tumor microenvironment confers highly malignant properties on pancreatic cancer cells , 2018, Oncogene.

[3]  A. Zhavoronkov,et al.  Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy , 2018, Nature Communications.

[4]  Camille Stephan-Otto Attolini,et al.  TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis , 2018, Nature.

[5]  M. Goumans,et al.  TGF-β Signaling in Control of Cardiovascular Function. , 2018, Cold Spring Harbor perspectives in biology.

[6]  R. Bourgon,et al.  TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.

[7]  Aroop Sircar,et al.  Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β , 2018, Science Translational Medicine.

[8]  T. Noda,et al.  TUFT1 interacts with RABGAP1 and regulates mTORC1 signaling , 2018, Cell Discovery.

[9]  S. Sakaguchi,et al.  Molecular control of regulatory T cell development and function. , 2017, Current opinion in immunology.

[10]  H. Aburatani,et al.  JUNB governs a feed-forward network of TGFβ signaling that aggravates breast cancer invasion , 2017, Nucleic acids research.

[11]  D. Sheppard,et al.  Blocking immunosuppression by human Tregs in vivo with antibodies targeting integrin αVβ8 , 2017, Proceedings of the National Academy of Sciences.

[12]  S. Lucas,et al.  Role of GARP in the activation of latent TGF-β1. , 2017, Molecular bioSystems.

[13]  S. Kaneko,et al.  Glycoprotein A repetitions predominant (GARP) positively regulates transforming growth factor (TGF) β3 and is essential for mouse palatogenesis , 2017, The Journal of Biological Chemistry.

[14]  K. Naka,et al.  Regulation of Hematopoiesis and Hematological Disease by TGF-β Family Signaling Molecules. , 2017, Cold Spring Harbor perspectives in biology.

[15]  Kohei Miyazono,et al.  Whole-Body Profiling of Cancer Metastasis with Single-Cell Resolution. , 2017, Cell reports.

[16]  Ming O. Li,et al.  Regulation of the Immune Response by TGF-β: From Conception to Autoimmunity and Infection. , 2017, Cold Spring Harbor perspectives in biology.

[17]  M. Hennig,et al.  Platelets subvert T cell immunity against cancer via GARP-TGFβ axis , 2017, Science Immunology.

[18]  Masayuki Yamamoto,et al.  The KEAP1–NRF2 System in Cancer , 2017, Front. Oncol..

[19]  H. Guan,et al.  CCT6A suppresses SMAD2 and promotes prometastatic TGF-&bgr; signaling , 2017, The Journal of clinical investigation.

[20]  Bin Zhou,et al.  Crosstalk between stromal cells and cancer cells in pancreatic cancer: New insights into stromal biology. , 2017, Cancer letters.

[21]  H. Ueno,et al.  Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer , 2017, Cancer Chemotherapy and Pharmacology.

[22]  H. Aburatani,et al.  Dynamics of chromatin accessibility during TGF-β-induced EMT of Ras-transformed mammary gland epithelial cells , 2017, Scientific Reports.

[23]  Thinzar M. Lwin,et al.  Color-coded intravital imaging demonstrates a transforming growth factor-β (TGF-β) antagonist selectively targets stromal cells in a human pancreatic-cancer orthotopic mouse model , 2017, Cell cycle.

[24]  Xiao-Fan Wang,et al.  TGF-β Family Signaling in the Control of Cell Proliferation and Survival. , 2017, Cold Spring Harbor perspectives in biology.

[25]  K. Miyazono,et al.  Regulation of TGF-β Family Signaling by Inhibitory Smads. , 2017, Cold Spring Harbor perspectives in biology.

[26]  R. Gomis,et al.  TGF-β Family Signaling in Tumor Suppression and Cancer Progression. , 2017, Cold Spring Harbor perspectives in biology.

[27]  R. Akhurst.  Targeting TGF-β Signaling for Therapeutic Gain. , 2017, Cold Spring Harbor perspectives in biology.

[28]  Kristofer C. Berrett,et al.  MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. , 2017, Cancer cell.

[29]  Ralph Weissleder,et al.  Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging , 2017, Nature Communications.

[30]  Ying E Zhang,et al.  Non-Smad Signaling Pathways of the TGF-β Family. , 2017, Cold Spring Harbor perspectives in biology.

[31]  T. Springer,et al.  Force interacts with macromolecular structure in activation of TGF-β , 2017, Nature.

[32]  P. Howe,et al.  Surface Expression of TGFβ Docking Receptor GARP Promotes Oncogenesis and Immune Tolerance in Breast Cancer. , 2016, Cancer research.

[33]  Xin-Hua Feng,et al.  Posttranslational Regulation of Smads. , 2016, Cold Spring Harbor perspectives in biology.

[34]  Minoru Terashima,et al.  MEG3 Long Noncoding RNA Contributes to the Epigenetic Regulation of Epithelial-Mesenchymal Transition in Lung Cancer Cell Lines* , 2016, The Journal of Biological Chemistry.

[35]  Gun Ho Jang,et al.  A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns , 2016, Nature.

[36]  K. Miyazono,et al.  RNA-binding motif protein 47 inhibits Nrf2 activity to suppress tumor growth in lung adenocarcinoma , 2016, Oncogene.

[37]  Luc Girard,et al.  ZEB1 drives epithelial-to-mesenchymal transition in lung cancer. , 2016, The Journal of clinical investigation.

[38]  H. Aburatani,et al.  Ras and TGF-β signaling enhance cancer progression by promoting the ΔNp63 transcriptional program , 2016, Science Signaling.

[39]  Luc Girard,et al.  ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs. , 2016, Cell reports.

[40]  C. Iacobuzio-Donahue,et al.  Pancreatic cancer biology and genetics from an evolutionary perspective , 2016, Nature Reviews Cancer.

[41]  R. Derynck,et al.  The Discovery and Early Days of TGF-β: A Historical Perspective. , 2016, Cold Spring Harbor perspectives in biology.

[42]  C. Heldin,et al.  Mechanisms of TGFβ-Induced Epithelial–Mesenchymal Transition , 2016, Journal of clinical medicine.

[43]  D. Rifkin,et al.  Regulation of the Bioavailability of TGF-β and TGF-β-Related Proteins. , 2016, Cold Spring Harbor perspectives in biology.

[44]  V. Syed,et al.  TGF‐β Signaling in Cancer , 2016, Journal of cellular biochemistry.

[45]  R. Derynck,et al.  TGF-β and the TGF-β Family: Context-Dependent Roles in Cell and Tissue Physiology. , 2016, Cold Spring Harbor perspectives in biology.

[46]  C. Iacobuzio-Donahue,et al.  TGF-β Tumor Suppression through a Lethal EMT , 2016, Cell.

[47]  R. Gibbs,et al.  Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.

[48]  G. Krenning,et al.  FGF2 inhibits endothelial–mesenchymal transition through microRNA-20a-mediated repression of canonical TGF-β signaling , 2016, Journal of Cell Science.

[49]  K. Miyazono,et al.  Mechanisms of action of bone morphogenetic proteins in cancer. , 2016, Cytokine & growth factor reviews.

[50]  Q. Song,et al.  Crosstalk between transforming growth factor-β signaling pathway and long non-coding RNAs in cancer. , 2016, Cancer letters.

[51]  K. Miyazono,et al.  MicroRNA‐31 is a positive modulator of endothelial–mesenchymal transition and associated secretory phenotype induced by TGF‐β , 2016, Genes to cells : devoted to molecular & cellular mechanisms.

[52]  N. Bardeesy,et al.  Pancreatic Cancer Metabolism: Breaking It Down to Build It Back Up. , 2015, Cancer discovery.

[53]  Stephen T. C. Wong,et al.  EMT is not required for lung metastasis but contributes to chemoresistance , 2015, Nature.

[54]  H. Utsumi,et al.  Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors , 2015, Cancer Chemotherapy and Pharmacology.

[55]  Masashi Fukayama,et al.  EZH2 promotes progression of small cell lung cancer by suppressing the TGF-β-Smad-ASCL1 pathway , 2015, Cell Discovery.

[56]  Martin Vingron,et al.  Comprehensive genomic profiles of small cell lung cancer , 2015, Nature.

[57]  L. Wood,et al.  RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma , 2015, Cell.

[58]  K. Miyazono,et al.  Smad4 Decreases the Population of Pancreatic Cancer-Initiating Cells through Transcriptional Repression of ALDH1A1. , 2015, The American journal of pathology.

[59]  Hans Clevers,et al.  Sequential cancer mutations in cultured human intestinal stem cells , 2015, Nature.

[60]  P. Delvenne,et al.  Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo , 2015, Science Translational Medicine.

[61]  Michael A. Choti,et al.  Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets , 2015, Nature Communications.

[62]  Judy Lieberman,et al.  Dysregulation of microRNA biogenesis and gene silencing in cancer , 2015, Science Signaling.

[63]  J. Kench,et al.  Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.

[64]  Takanori Kanai,et al.  Modeling colorectal cancer using CRISPR-Cas9–mediated engineering of human intestinal organoids , 2015, Nature Medicine.

[65]  John T. Poirier,et al.  DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2 , 2015 .

[66]  T. Sellers,et al.  Long Non-coding RNAs (LncRNA) Regulated by Transforming Growth Factor (TGF) β , 2015, The Journal of Biological Chemistry.

[67]  R. Zhu,et al.  Heme Oxygenase-1 Restores Impaired GARP+CD4+CD25+ Regulatory T Cells from Patients with Acute Coronary Syndrome by Upregulating LAP and GARP Expression on Activated T Lymphocytes , 2015, Cellular Physiology and Biochemistry.

[68]  R. Derynck,et al.  Signaling pathway cooperation in TGF-β-induced epithelial-mesenchymal transition. , 2014, Current opinion in cell biology.

[69]  Jingyu Zhang,et al.  TGF-β–induced epithelial-to-mesenchymal transition proceeds through stepwise activation of multiple feedback loops , 2014, Science Signaling.

[70]  G. Wahl,et al.  Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy , 2014, Cell.

[71]  G. Tellides,et al.  Fibroblast growth factor receptor 1 is a key inhibitor of TGFβ signaling in the endothelium , 2014, Science Signaling.

[72]  Xiaohong Xu,et al.  Neutralizing murine TGFβR2 promotes a differentiated tumor cell phenotype and inhibits pancreatic cancer metastasis. , 2014, Cancer research.

[73]  H. Aburatani,et al.  A Smad3 and TTF-1/NKX2-1 complex regulates Smad4-independent gene expression , 2014, Cell Research.

[74]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[75]  M. Korc,et al.  Pancreatic cancer stroma: friend or foe? , 2014, Cancer cell.

[76]  F. Liu,et al.  A long noncoding RNA activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma. , 2014, Cancer Cell.

[77]  Samy Lamouille,et al.  Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.

[78]  L. Qi,et al.  Impaired Circulating CD4+LAP+ Regulatory T Cells in Patients with Acute Coronary Syndrome and Its Mechanistic Study , 2014, PloS one.

[79]  C. Heldin,et al.  TRAF6 Stimulates the Tumor-Promoting Effects of TGFβ Type I Receptor Through Polyubiquitination and Activation of Presenilin 1 , 2014, Science Signaling.

[80]  Wai Leong Tam,et al.  The epigenetics of epithelial-mesenchymal plasticity in cancer , 2013, Nature Medicine.

[81]  Eshel Ben-Jacob,et al.  MicroRNA-based regulation of epithelial–hybrid–mesenchymal fate determination , 2013, Proceedings of the National Academy of Sciences.

[82]  H. Moses,et al.  The roles of TGFβ in the tumour microenvironment , 2013, Nature Reviews Cancer.

[83]  G. Bommer,et al.  GARP Is Regulated by miRNAs and Controls Latent TGF-β1 Production by Human Regulatory T Cells , 2013, PloS one.

[84]  Craig Mickanin,et al.  TRAF4 promotes TGF-β receptor signaling and drives breast cancer metastasis. , 2013, Molecular cell.

[85]  Bradley P. Coe,et al.  EZH2 Promotes E2F-Driven SCLC Tumorigenesis through Modulation of Apoptosis and Cell-Cycle Regulation , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[86]  Jianhua Xing,et al.  Coupled reversible and irreversible bistable switches underlying TGFβ-induced epithelial to mesenchymal transition. , 2013, Biophysical journal.

[87]  Tomoya Yamaguchi,et al.  NKX2-1/TTF-1: an enigmatic oncogene that functions as a double-edged sword for cancer cell survival and progression. , 2013, Cancer cell.

[88]  Takanori Fujita,et al.  PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer , 2013, Scientific Reports.

[89]  P. Lipsky,et al.  miR-142-3p Is Involved in CD25+ CD4 T Cell Proliferation by Targeting the Expression of Glycoprotein A Repetitions Predominant , 2013, The Journal of Immunology.

[90]  R. Evans,et al.  A Vitamin D Receptor/SMAD Genomic Circuit Gates Hepatic Fibrotic Response , 2013, Cell.

[91]  L. Wakefield,et al.  Beyond TGFβ: roles of other TGFβ superfamily members in cancer , 2013, Nature Reviews Cancer.

[92]  Austin Miller,et al.  Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. , 2013, Cancer research.

[93]  Samy Lamouille,et al.  Regulation of epithelial-mesenchymal and mesenchymal-epithelial transitions by microRNAs. , 2013, Current opinion in cell biology.

[94]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[95]  R. Derynck,et al.  TGF-β family signaling in stem cells. , 2013, Biochimica et biophysica acta.

[96]  Samy Lamouille,et al.  TGF-&bgr; signaling and epithelial–mesenchymal transition in cancer progression , 2013, Current opinion in oncology.

[97]  G. M. Di Guglielmo,et al.  Atypical Protein Kinase C Phosphorylates Par6 and Facilitates Transforming Growth Factor β-Induced Epithelial-to-Mesenchymal Transition , 2012, Molecular and Cellular Biology.

[98]  R. Bernards,et al.  MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling , 2012, Cell.

[99]  Daniel G. Anderson,et al.  FGF regulates TGF-β signaling and endothelial-to-mesenchymal transition via control of let-7 miRNA expression. , 2012, Cell reports.

[100]  Lincoln D. Stein,et al.  Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes , 2012, Nature.

[101]  M. Stearns,et al.  c-Myc expression and MEK1-induced Erk2 nuclear localization are required for TGF-beta induced epithelial-mesenchymal transition and invasion in prostate cancer. , 2012, Carcinogenesis.

[102]  R. Weinberg,et al.  Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. , 2012, Seminars in cancer biology.

[103]  A. Hata,et al.  Targeting the TGFβ signalling pathway in disease , 2012, Nature Reviews Drug Discovery.

[104]  Michael Peyton,et al.  Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. , 2012, Cancer discovery.

[105]  A. Moustakas,et al.  Context-dependent action of transforming growth factor β family members on normal and cancer stem cells. , 2012, Current pharmaceutical design.

[106]  R. Losson,et al.  Tif1γ suppresses murine pancreatic tumoral transformation by a Smad4-independent pathway. , 2012, The American journal of pathology.

[107]  K. Miyazono,et al.  Genome-wide mechanisms of Smad binding , 2012, Oncogene.

[108]  James W. Smyth,et al.  TGF-β-induced activation of mTOR complex 2 drives epithelial–mesenchymal transition and cell invasion , 2012, Development.

[109]  Giulio Gabbiani,et al.  The role of the myofibroblast in tumor stroma remodeling , 2012, Cell adhesion & migration.

[110]  K. Miyazono,et al.  Tumor-promoting functions of transforming growth factor-β in progression of cancer , 2012, Upsala journal of medical sciences.

[111]  M. Kanda,et al.  Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. , 2012, Gastroenterology.

[112]  Y. Inoue,et al.  The roles of TGF-β signaling in carcinogenesis and breast cancer metastasis , 2012, Breast Cancer.

[113]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[114]  T. Springer,et al.  GARP regulates the bioavailability and activation of TGFβ , 2012, Molecular biology of the cell.

[115]  H. van Dam,et al.  Key signaling nodes in mammary gland development and cancer: Smad signal integration in epithelial cell plasticity , 2012, Breast Cancer Research.

[116]  Hiroshi I. Suzuki,et al.  TGF-β-induced mesenchymal transition of MS-1 endothelial cells requires Smad-dependent cooperative activation of Rho signals and MRTF-A. , 2012, Journal of biochemistry.

[117]  K. Miyazono,et al.  TGF-β-induced epithelial-mesenchymal transition of A549 lung adenocarcinoma cells is enhanced by pro-inflammatory cytokines derived from RAW 264.7 macrophage cells. , 2012, Journal of biochemistry.

[118]  D. Patel,et al.  A Poised Chromatin Platform for TGF-β Access to Master Regulators , 2011, Cell.

[119]  A. Menssen,et al.  miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions , 2011, Cell cycle.

[120]  T. Watabe,et al.  Roles of TGF-β Signals in Endothelial-Mesenchymal Transition during Cardiac Fibrosis , 2011, International journal of inflammation.

[121]  Manuel Hidalgo,et al.  Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. , 2011, Cell stem cell.

[122]  K. Miyazono,et al.  TGF-β drives epithelial-mesenchymal transition through δEF1-mediated downregulation of ESRP , 2011, Oncogene.

[123]  David A. Orlando,et al.  Master Transcription Factors Determine Cell-Type-Specific Responses to TGF-β Signaling , 2011, Cell.

[124]  M. Anderton,et al.  Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors , 2011, Toxicologic pathology.

[125]  Richard O Hynes,et al.  Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. , 2011, Cancer cell.

[126]  R. Hruban,et al.  Pancreatic cancer , 2011, The Lancet.

[127]  T. Walz,et al.  Latent TGF-β structure and activation , 2011, Nature.

[128]  H. Aburatani,et al.  Cell Type-specific Target Selection by Combinatorial Binding of Smad2/3 Proteins and Hepatocyte Nuclear Factor 4α in HepG2 Cells , 2011, The Journal of Biological Chemistry.

[129]  Sophia Hsin-Jung Li,et al.  Paracrine and Autocrine Signals Induce and Maintain Mesenchymal and Stem Cell States in the Breast , 2011, Cell.

[130]  M. F. Shannon,et al.  An autocrine TGF-β/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition , 2011, Molecular biology of the cell.

[131]  M. Kimura,et al.  Bmi1 regulates cell fate via tumor suppressor WWOX repression in small‐cell lung cancer cells , 2011, Cancer science.

[132]  C. Heldin,et al.  TRAF6 ubiquitinates TGFβ type I receptor to promote its cleavage and nuclear translocation in cancer , 2011, Nature communications.

[133]  H. Weiss,et al.  mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. , 2011, Cancer research.

[134]  Derek Y. Chiang,et al.  Suppression of Lung Adenocarcinoma Progression by Nkx2-1 , 2011, Nature.

[135]  T. Shibata,et al.  TGF-β regulates isoform switching of FGF receptors and epithelial–mesenchymal transition , 2011, The EMBO journal.

[136]  Robert A. Weinberg,et al.  Autocrine TGF-β and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts , 2010, Proceedings of the National Academy of Sciences.

[137]  Simone Brabletz,et al.  The ZEB/miR‐200 feedback loop—a motor of cellular plasticity in development and cancer? , 2010, EMBO reports.

[138]  Richard A. Flavell,et al.  The polarization of immune cells in the tumour environment by TGFβ , 2010, Nature Reviews Immunology.

[139]  R. Morita,et al.  Smad2 and Smad3 Are Redundantly Essential for the TGF-β–Mediated Regulation of Regulatory T Plasticity and Th1 Development , 2010, The Journal of Immunology.

[140]  Yu Wakabayashi,et al.  Cellular and molecular basis for the regulation of inflammation by TGF-beta. , 2010, Journal of biochemistry.

[141]  Kohei Miyazono,et al.  TGFβ signalling: a complex web in cancer progression , 2010, Nature Reviews Cancer.

[142]  Kristian Pietras,et al.  Hallmarks of cancer: interactions with the tumor stroma. , 2010, Experimental cell research.

[143]  John D. Minna,et al.  Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy , 2010, Cancer and Metastasis Reviews.

[144]  Jacques Ferlay,et al.  NORDCAN – a Nordic tool for cancer information, planning, quality control and research , 2010, Acta oncologica.

[145]  P. Coulie,et al.  Membrane protein GARP is a receptor for latent TGF‐β on the surface of activated human Treg , 2009, European journal of immunology.

[146]  D. Unutmaz,et al.  Expression of GARP selectively identifies activated human FOXP3+ regulatory T cells , 2009, Proceedings of the National Academy of Sciences.

[147]  E. Shevach,et al.  GARP (LRRC32) is essential for the surface expression of latent TGF-β on platelets and activated FOXP3+ regulatory T cells , 2009, Proceedings of the National Academy of Sciences.

[148]  Giovanni Parmigiani,et al.  SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer , 2009, Clinical Cancer Research.

[149]  G. Alexe,et al.  Transforming growth factor-β signaling: emerging stem cell target in metastatic breast cancer? , 2009, Breast Cancer Research and Treatment.

[150]  M. Probst-Kepper,et al.  GARP: a key receptor controlling FOXP3 in human regulatory T cells , 2009, Journal of cellular and molecular medicine.

[151]  H. Aburatani,et al.  Diffuse-Type Gastric Carcinoma: Progression, Angiogenesis, and Transforming Growth Factor β Signaling , 2009 .

[152]  Kohei Miyazono,et al.  Thyroid transcription factor-1 inhibits transforming growth factor-beta-mediated epithelial-to-mesenchymal transition in lung adenocarcinoma cells. , 2009, Cancer research.

[153]  Claude C. Warzecha,et al.  ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. , 2009, Molecular cell.

[154]  A. Ostman,et al.  Cancer-associated fibroblasts and tumor growth--bystanders turning into key players. , 2009, Current opinion in genetics & development.

[155]  M. Brock,et al.  Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer. , 2009, Cancer research.

[156]  Takeshi Imamura,et al.  Role of Ras Signaling in the Induction of Snail by Transforming Growth Factor-β* , 2009, Journal of Biological Chemistry.

[157]  J. Melamed,et al.  Perturbation of transforming growth factor (TGF)-ß1 association with latent TGF-β binding protein yields inflammation and tumors , 2008, Proceedings of the National Academy of Sciences.

[158]  Chris I. Jones,et al.  Functional genomics in zebrafish permits rapid characterization of novel platelet membrane proteins , 2008, Blood.

[159]  C. Heldin,et al.  The type I TGF-β receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner , 2008, Nature Cell Biology.

[160]  M. Yamashita,et al.  TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. , 2008, Molecular cell.

[161]  A. Cheung,et al.  p70 S6 kinase promotes epithelial to mesenchymal transition through snail induction in ovarian cancer cells. , 2008, Cancer research.

[162]  R. Flavell,et al.  TGF-β: A Master of All T Cell Trades , 2008, Cell.

[163]  J. Massagué,et al.  TGFβ in Cancer , 2008, Cell.

[164]  D. Unutmaz,et al.  Identification of a Regulatory T Cell Specific Cell Surface Molecule that Mediates Suppressive Signals and Induces Foxp3 Expression , 2008, PloS one.

[165]  A. Kulkarni,et al.  A critical function for TGF-β signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells , 2008, Nature Immunology.

[166]  T. Brabletz,et al.  A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells , 2008, EMBO reports.

[167]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[168]  G. Goodall,et al.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.

[169]  Roger R. Gomis,et al.  TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4 , 2008, Cell.

[170]  G. Tortora,et al.  LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis , 2008, Molecular Cancer Therapeutics.

[171]  Sun-Mi Park,et al.  The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. , 2008, Genes & development.

[172]  J. Groffen,et al.  SMAD3 prevents binding of NKX2.1 and FOXA1 to the SpB promoter through its MH1 and MH2 domains , 2007, Nucleic acids research.

[173]  Liang Xie,et al.  Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. , 2007, Cancer research.

[174]  Jing Qing,et al.  TGF‐β activates Erk MAP kinase signalling through direct phosphorylation of ShcA , 2007 .

[175]  Samy Lamouille,et al.  Cell size and invasion in TGF-β–induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway , 2007, The Journal of cell biology.

[176]  Terry B. Strom,et al.  IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells , 2007, Nature.

[177]  Alison Murphy,et al.  Inhibition of Transforming Growth Factor β Signaling Reduces Pancreatic Adenocarcinoma Growth and Invasiveness , 2007, Molecular Pharmacology.

[178]  R. Hruban,et al.  Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. , 2007, Cancer cell.

[179]  R. Beroukhim,et al.  Molecular definition of breast tumor heterogeneity. , 2007, Cancer cell.

[180]  M. Farrar,et al.  IL-2 Receptor β-Dependent STAT5 Activation Is Required for the Development of Foxp3+ Regulatory T Cells1 , 2007, The Journal of Immunology.

[181]  H. Moses,et al.  Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. , 2006, Genes & development.

[182]  Gerald C. Chu,et al.  Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. , 2006, Genes & development.

[183]  Brian Bierie,et al.  Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer , 2006, Nature Reviews Cancer.

[184]  M. Fraga,et al.  The Polycomb group protein EZH2 directly controls DNA methylation , 2006, Nature.

[185]  Zhenzhen Wang,et al.  In vivo disruption of TGF-beta signaling by Smad7 leads to premalignant ductal lesions in the pancreas. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[186]  C. Hill,et al.  Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. , 2006, Cytokine & growth factor reviews.

[187]  R. J. Hocking,et al.  TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. , 2006, Immunity.

[188]  R. Derynck,et al.  SPECIFICITY AND VERSATILITY IN TGF-β SIGNALING THROUGH SMADS , 2005 .

[189]  C. Heldin,et al.  Non-Smad TGF-β signals , 2005, Journal of Cell Science.

[190]  F. Sutterwala,et al.  Transforming growth factor-β controls T helper type 1 cell development through regulation of natural killer cell interferon-γ , 2005, Nature Immunology.

[191]  Yue Zhang,et al.  Regulation of the Polarity Protein Par6 by TGFß Receptors Controls Epithelial Cell Plasticity , 2005, Science.

[192]  A. Sánchez-Capelo.  Dual role for TGF-β1 in apoptosis , 2005 .

[193]  H. Moses,et al.  Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. , 2004, Neoplasia.

[194]  D. Rifkin,et al.  Integrin αVβ6-mediated activation of latent TGF-β requires the latent TGF-β binding protein-1 , 2004, The Journal of cell biology.

[195]  M. Washington,et al.  TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia , 2004, Science.

[196]  S. Nishikawa,et al.  TGF-β receptor kinase inhibitor enhances growth and integrity of embryonic stem cell–derived endothelial cells , 2003, The Journal of cell biology.

[197]  Li Li,et al.  Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3 , 2003, The Journal of experimental medicine.

[198]  W. N. Pappano,et al.  Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[199]  E. Petricoin,et al.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.

[200]  J. Massagué,et al.  Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer , 2003, Nature Reviews Cancer.

[201]  A. Berns,et al.  Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. , 2003, Cancer cell.

[202]  L. Wakefield,et al.  The two faces of transforming growth factor β in carcinogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[203]  D. Rifkin,et al.  Latent Transforming Growth Factor β-binding Protein 1 Interacts with Fibrillin and Is a Microfibril-associated Protein* , 2003, The Journal of Biological Chemistry.

[204]  J. Downward,et al.  Ras and TGFβ cooperatively regulate epithelial cell plasticity and metastasis , 2002, The Journal of Cell Biology.

[205]  J. Cameron,et al.  The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[206]  R. Hruban,et al.  ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[207]  R H Hruban,et al.  Progression model for pancreatic cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[208]  R. Hruban,et al.  Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. , 2000, Cancer research.

[209]  Jeffrey B. Kopp,et al.  TGF- and fibrosis , 1999 .

[210]  K. Shim,et al.  Elevated serum levels of transforming growth factor-beta1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection. , 1999, Cancer.

[211]  R. Hruban,et al.  Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. , 1998, Cancer research.

[212]  R. Hruban,et al.  Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. , 1998, Cancer research.

[213]  U. Mansmann,et al.  Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma. , 1998, British Journal of Cancer.

[214]  H. Poulsen,et al.  High value of the radiobiological parameter Dq correlates to expression of the transforming growth factor beta type II receptor in a panel of small cell lung cancer cell lines. , 1998, Lung cancer.

[215]  Kohei Miyazono,et al.  TGF-β signalling from cell membrane to nucleus through SMAD proteins , 1997, Nature.

[216]  Scott E. Kern,et al.  DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1 , 1996, Science.

[217]  M. Anscher,et al.  Elevated Plasma Transforming Growth Factor-β1 Levels in Breast Cancer Patients Decrease After Surgical Removal of the Tumor , 1995, Annals of surgery.

[218]  R. Derynck,et al.  TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors , 1994, The Journal of cell biology.

[219]  D. Birnbaum,et al.  The GARP gene encodes a new member of the family of leucine-rich repeat-containing proteins. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[220]  K. Kinzler,et al.  The multistep nature of cancer. , 1993, Trends in genetics : TIG.

[221]  M. Sporn,et al.  Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[222]  D. Birnbaum,et al.  DNA amplification at 11q13.5-q14 in human breast cancer. , 1992, Oncogene.

[223]  G. Proetzel,et al.  Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease , 1992, Nature.

[224]  J. Dufour,et al.  Cell lines , 2012, Spermatogenesis.

[225]  D. Constam,et al.  Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. , 1992, Journal of immunology.

[226]  R. Lauro,et al.  The transcription factor TTF-1 is expressed at the onset of thyroid and lung morphogenesis and in restricted regions of the foetal brain. , 1991, Development.

[227]  M. Sporn,et al.  Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. , 1983, The Journal of biological chemistry.

[228]  M. Sporn,et al.  New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[229]  H. Moses,et al.  Transforming growth factor production by chemically transformed cells. , 1981, Cancer research.

[230]  H. Kocher,et al.  Pancreatic Cancer , 2019, Methods in Molecular Biology.

[231]  Xiaohua Yan,et al.  Feedback regulation of TGF-β signaling. , 2018, Acta biochimica et biophysica Sinica.

[232]  P. ten Dijke,et al.  Targeting TGF-β Signaling in Cancer. , 2017, Trends in cancer.

[233]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[234]  Jean Paul Thiery,et al.  EMT: 2016 , 2016, Cell.

[235]  M. Lazzara,et al.  ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition. , 2014, Cancer research.

[236]  M. Sporn,et al.  Transforming Growth Factor-@ in Human Platelets , 2011 .

[237]  M. Hidalgo.  Pancreatic cancer. , 2010, The New England journal of medicine.

[238]  K. Luo,et al.  Ski and SnoN, potent negative regulators of TGF-β signaling , 2009, Cell Research.

[239]  M. Korc,et al.  Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis. , 2002, Molecular cancer therapeutics.

[240]  E. Montgomery,et al.  すい臓癌におけるACVR1B(ALK4、1B型アクチビン受容体)遺伝子の突然変異 , 2001 .

[241]  M Reiss,et al.  Frequent inactivation of the transforming growth factor beta type II receptor in small-cell lung carcinoma cells. , 1997, Oncology research.